Cargando…
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
BACKGROUND: Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis can prevent such events is unknown. OBJECTIVES: The purpose of this study was to evaluate whether extended-duration rivaroxaban red...
Autores principales: | Spyropoulos, Alex C., Ageno, Walter, Albers, Gregory W., Elliott, C. Gregory, Halperin, Jonathan L., Hiatt, William R., Maynard, Gregory A., Steg, P. Gabriel, Weitz, Jeffrey I., Lu, Wentao, Spiro, Theodore E., Barnathan, Elliot S., Raskob, Gary. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308003/ https://www.ncbi.nlm.nih.gov/pubmed/32586587 http://dx.doi.org/10.1016/j.jacc.2020.04.071 |
Ejemplares similares
-
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022) -
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022) -
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021) -
Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021) -
Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)